Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1990 Dec;47(6):899–903.

Maternal serum alpha-fetoprotein screening activities of state health agencies: a survey.

G C Cunningham 1, K W Kizer 1
PMCID: PMC1683902  PMID: 1700603

Abstract

Maternal serum alpha-fetoprotein (MSAFP) screening has been demonstrated to be cost-effective on a population basis and is becoming standard practice. The American Society of Human Genetics has twice published policy statements to define the essential elements of a quality screening program. The present study reviewed the impact of these policy statements on state public-health agencies with respect to regulation or provision of MSAFP screening in their jurisdictions. With a few exceptions, states have not elected to play a major role in provision or regulation of this test. There is need to address issues of funding, standards, and data collection in a collaborative effort, if policy statements on genetic services are to be translated into effective state population screening.

Full text

PDF
902

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Garver K. L. Update on MSAFP policy statement from the American Society of Human Genetics. Am J Hum Genet. 1989 Aug;45(2):332–334. [PMC free article] [PubMed] [Google Scholar]
  2. Haddow J. E., Milunsky A. Deregulation of screening for alpha-fetoprotein in pregnancy. N Engl J Med. 1984 Jun 21;310(25):1669–1670. doi: 10.1056/NEJM198406213102514. [DOI] [PubMed] [Google Scholar]
  3. Lomas J., Anderson G. M., Domnick-Pierre K., Vayda E., Enkin M. W., Hannah W. J. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 1989 Nov 9;321(19):1306–1311. doi: 10.1056/NEJM198911093211906. [DOI] [PubMed] [Google Scholar]
  4. Main D. M., Mennuti M. T. Neural tube defects: issues in prenatal diagnosis and counselling. Obstet Gynecol. 1986 Jan;67(1):1–16. [PubMed] [Google Scholar]
  5. Maternal serum alpha-fetoprotein screening for neural tube defects. Results of a consensus meeting. Prenat Diagn. 1985 Jan-Feb;5(1):77–83. doi: 10.1002/pd.1970050114. [DOI] [PubMed] [Google Scholar]
  6. Palomaki G. E., Knight G. J., Holman M. S., Haddow J. E. Maternal serum alpha-fetoprotein screening for fetal Down syndrome in the United States: results of a survey. Am J Obstet Gynecol. 1990 Feb;162(2):317–321. doi: 10.1016/0002-9378(90)90377-j. [DOI] [PubMed] [Google Scholar]
  7. Tosi L. L., Detsky A. S., Roye D. P., Morden M. L. When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings? CMAJ. 1987 Feb 1;136(3):255–265. [PMC free article] [PubMed] [Google Scholar]
  8. Wald N. J., Cuckle H. S. Recent advances in screening for neural tube defects and Down's syndrome. Baillieres Clin Obstet Gynaecol. 1987 Sep;1(3):649–676. doi: 10.1016/s0950-3552(87)80010-x. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES